CD81 is a Novel Immunotherapeutic Target for B Cell Lymphoma

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2019 May 25

PMID 31123084

Citations 20

Authors

Felipe Vences-Catalan

Chiung-Chi Kuo

Ranjani Rajapaksa

Caroline Duault

Noemi Andor

Debra K Czerwinski

Ronald Levy

Shoshana Levy

Affiliations

Soon will be listed here.

Abstract

The tetraspanin was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target , has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as effectively as rituximab, which is a standard treatment for B cell lymphoma. Importantly, unlike rituximab, which depletes normal as well as malignant B cells, 5A6 selectively kills human lymphoma cells from fresh biopsy specimens while sparing the normal lymphoid cells in the tumor microenvironment. The 5A6 antibody showed a good safety profile when administered to a mouse transgenic for human CD81. Taken together, these data provide the rationale for the development of the 5A6 mAb and its humanized derivatives as a novel treatment against B cell lymphoma.

Citing Articles

Distinctive function of Tetraspanins: Implication in viral infections.

Zhang Y, Pan C, Wang S, Zhou Y, Chen J, Yu X Virulence. 2025; 16(1):2474188.

PMID: 40053412 PMC: 11901453. DOI: 10.1080/21505594.2025.2474188.

Proteomic Profiling of Lymph Nodes Differentiates Classic Hodgkin Lymphoma With and Without Skeletal Involvement.

Andersen M, Wolter K, Enemark M, Pedersen M, Gormsen L, Lauridsen K Eur J Haematol. 2024; 114(1):173-185.

PMID: 39394762 PMC: 11613579. DOI: 10.1111/ejh.14326.

A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors.

Schultheiss C, Paschold L, Mohebiany A, Escher M, Kattimani Y, Muller M Sci Adv. 2024; 10(34):eadl3975.

PMID: 39167656 PMC: 11338232. DOI: 10.1126/sciadv.adl3975.

Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche.

de Oliveira K, Bang-Rudenstam A, Beyer S, Boukredine A, Talbot H, Governa V Acta Neuropathol Commun. 2024; 12(1):35.

PMID: 38414005 PMC: 10898066. DOI: 10.1186/s40478-024-01740-z.

LincRNA01703 Facilitates CD81 Exosome Secretion to Inhibit Lung Adenocarcinoma Metastasis via the Rab27a/SYTL1/CD81 Complex.

Huang Y, Guo S, Lin Y, Huo L, Yan H, Lin Z Cancers (Basel). 2023; 15(24).

PMID: 38136327 PMC: 10742068. DOI: 10.3390/cancers15245781.

References

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

Higginbottom A, Quinn E, Kuo C, Flint M, WILSON L, Bianchi E . Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol. 2000; 74(8):3642-9. PMC: 111874. DOI: 10.1128/jvi.74.8.3642-3649.2000. View

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

Masciopinto F, Freer G, Burgio V, Levy S, Galli-Stampino L, Bendinelli M . Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology. 2002; 304(2):187-96. DOI: 10.1006/viro.2002.1631. View

Bradbury L, Kansas G, Levy S, Evans R, Tedder T . The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol. 1992; 149(9):2841-50. View

Spira G, Scharff M . Identification of rare immunoglobulin switch variants using the ELISA spot assay. J Immunol Methods. 1992; 148(1-2):121-9. DOI: 10.1016/0022-1759(92)90165-p. View

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C . Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23(18):4117-26. DOI: 10.1200/JCO.2005.09.131. View

Oren R, Takahashi S, Doss C, Levy R, Levy S . TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol. 1990; 10(8):4007-15. PMC: 360911. DOI: 10.1128/mcb.10.8.4007-4015.1990. View

Yalaoui S, Zougbede S, Charrin S, Silvie O, Arduise C, Farhati K . Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain. PLoS Pathog. 2008; 4(2):e1000010. PMC: 2279262. DOI: 10.1371/journal.ppat.1000010. View

10.

Hemler M . Targeting of tetraspanin proteins--potential benefits and strategies. Nat Rev Drug Discov. 2008; 7(9):747-58. PMC: 4737550. DOI: 10.1038/nrd2659. View

11.

Houot R, Levy R . Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev. 2008; 23(3):137-42. DOI: 10.1016/j.blre.2008.09.001. View

12.

Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S . Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009; 113(20):4885-93. DOI: 10.1182/blood-2008-08-175208. View

13.

Stolz C, Schuler M . Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma. 2009; 50(6):873-85. DOI: 10.1080/10428190902878471. View

14.

Luo R, Zhao S, Tibshirani R, Myklebust J, Sanyal M, Fernandez R . CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum Pathol. 2009; 41(2):271-80. PMC: 2813949. DOI: 10.1016/j.humpath.2009.07.022. View

15.

van Zelm M, Smet J, Adams B, Mascart F, Schandene L, Janssen F . CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest. 2010; 120(4):1265-74. PMC: 2846042. DOI: 10.1172/JCI39748. View

16.

Gomez-Abad C, Pisonero H, Blanco-Aparicio C, Roncador G, Gonzalez-Menchen A, Martinez-Climent J . PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood. 2011; 118(20):5517-27. DOI: 10.1182/blood-2011-03-344374. View

17.

Paiva B, Gutierrez N, Chen X, Vidriales M, Montalban M, Rosinol L . Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia. 2012; 26(8):1862-9. DOI: 10.1038/leu.2012.42. View

18.

Scott A, Wolchok J, Old L . Antibody therapy of cancer. Nat Rev Cancer. 2012; 12(4):278-87. DOI: 10.1038/nrc3236. View

19.

Takahashi S, Doss C, Levy S, Levy R . TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J Immunol. 1990; 145(7):2207-13. View

20.

Beckwith K, Frissora F, Stefanovski M, Towns W, Cheney C, Mo X . The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014; 28(7):1501-10. PMC: 4090271. DOI: 10.1038/leu.2014.32. View